In an interview during ASH 2025, Ontada's Ira Zackson, MD explores the role of BTK inhibitors in chronic lymphocytic leukemia ...
Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.
Good morning, and welcome to the Nurix Therapeutics Conference Call. I'm Arthur Sands, President and CEO. And I'm joined today on this call by Gwenn Hansen, our Chief Scientific Officer; Paula ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback